No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 10 of the 32 quarters in the window, leaving 22 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 4.5x · 10Y median 27.4x · 13th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 33
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2023-12-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2023-12-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2023-12-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T20:37:57.990Z. Latest historical point 2023-12-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Q32 Bio Inc. (QTTB) stock was $8.11 as of Oct 6, 2026, 4:00 PM EDT, down 3.11% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +301.7% · 3-year avg -25.4%/yr · 5-year avg -41.5%/yr
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.36
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.44
vs Estimate
$-0.54
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1QTTB | $241.39M | $8.11 | -3.11% | +301.66% | -41.51% | N/A | N/A |
| 2QSI | $241.34M | $1.22 | -4.69% | -25.48% | -31.06% | N/A | vs QTTB |
| 3LFCR | $241.94M | $6.45 | -1.07% | -6.56% | -7.12% | -6.99% | vs QTTB |
| 4IPSC | $239.02M | $1.32 | -10.81% | +186.88% | -42.05% | N/A | vs QTTB |
| 5HITI | $239.01M | $2.72 | -0.37% | -23.43% | -14.29% | N/A | vs QTTB |
| 6IVVD | $237.57M | $0.81 | -3.91% | -27.54% | -51.69% | N/A | vs QTTB |
$0.00
vs Estimate
$1.00M
Consensus Rating
Based on 5 analysts
Average Price Target
$39.60
+388.3% upside
Low
$29.00
Current
$8.11
High
$59.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.39 | $-0.33 | $-0.30 | 4 |
| Quarter ending Dec 2026 | $-0.35 | $-0.31 | $-0.23 | 4 |
| Quarter ending Mar 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Quarter ending Jun 2027 | $-0.48 | $-0.48 | $-0.48 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.59 | $-1.49 | $-1.39 | 5 |
| FY 2027 | $-2.43 | $-2.07 | $-1.72 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $666667.00 | $666667.00 | $666667.00 | 5 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $333333.00 | $333333.00 | $333333.00 | 5 |
| FY 2027 | $833333.00 | $833333.00 | $833333.00 | 5 |
